Larimar Therapeutics, Inc. Company Profile & Data: stocks, market cap, financials, digital and more

                        
Company
Larimar Therapeutics, Inc.Headquarters: Bala Cynwyd, 
                        PA, United States
                    
Employees: 28
CEO: Dr. Carole S. Ben-Maimon

                                    NASDAQ: LRMR
                                
                                            +5.96%
                                            
Market Cap$204.9 Million

                        USD as of July 1, 2025
                    
                            Market Cap History

Larimar Therapeutics, Inc. Categories

United States Healthcare Biotechnology
United States Healthcare United States Biotechnology

Larimar Therapeutics, Inc. market capitalization over time

Evolution of Larimar Therapeutics, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Larimar Therapeutics, Inc.

Top Competitors by Market Capitalization

Industry: Biotechnology

Company	Market Cap (USD)
Novo Nordisk	$309.91 B
Vertex Pharmaceuticals Incorporated	$117.36 B
CSL Limited	$95.75 B
Regeneron Pharmaceuticals, Inc.	$59.14 B
Marinomed Biotech AG	$58.56 B

Sector:

Company	Market Cap (USD)
Lilly	$699.59 B
Johnson & Johnson	$374.29 B
AbbVie	$336.94 B
Novo Nordisk	$309.91 B
UnitedHealth Group	$279.90 B

Detailed Description

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare and progressive genetic disease. Larimar Therapeutics, Inc. is headquartered in Bala Cynwyd, Pennsylvania.

Financials

Last Financial Reports Date	Dec. 31, 2023
Revenue TTM	$0
EBITDA	$-41,447,000
Gross Profit TTM	$0
Profit Margin	0.00%
Operating Margin	0.00%
Quarterly Revenue Growth	%